News
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Top-line Data On Track to be Reported During Q3 2018 Oxford, UK, and Cambridge, MA, US, 19 April 2018 - Summit Therapeutics plc ...
DMD affects an estimated one in every 3,500–5,000 male births, with an estimated 12,000–15,000 patients in the United States and approximately 25,000 patients in Europe.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback